tirzepatide non responder GLP-1 nonresponders: Up to 1 in 5 people don't lose weight When GLP-1s Fall Short: Some

No phone support exists

Constant cravings Weight that wont budge Low energy or metabolic slowdown Hormonal resistance GLP-1 therapy helps address the underlying metabolic factors that make weight loss difficult

Despite Wegovy and Zepbound being approved for patients with a body mass index of 30 or greater, and 27 or greater for those with at least one weight-related ailment, some insurance plans require a higher BMI or additional criteria for coverageif they cover medications for obesity at all

The medication side effects often resolve with time, but if they are severe enough, some patients may decide its just not worth seeing what happens, Garcia-Webb says